Mylan Prepares To Launch Insulin Glargine After Another Lantus IP Win
IPR Victory In US Follows Favorable District Court Ruling In March
Executive Summary
Mylan says it is now ready to launch its Semglee insulin glargine rival to Sanofi’s Lantus in the US upon FDA approval, after removing the final intellectual-property barriers by way of a favorable inter partes review decision.
You may also be interested in...
US Court Rules In Favor Of Viatris For Interchangeable Semglee
Viatris and Biocon continue marketing their recently launched interchangeable biosimilar Semglee (insulin glargine-yfgn) as a US appeals court affirms that the challenged claims of five of Sanofi’s Lantus SoloSTAR device patents are unpatentable.
Mylan And Biocon Launch Semglee Insulin Glargine In US
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.
Lannett Advances Its Insulin Glargine
After receiving “positive feedback” from the US Food and Drug Administration on its biosimilar insulin glargine, Lannett plans to move forward with its development activity.